Clinical Genomics owns proprietary technologies designed to improve the early detection of cancer.
We have applied our patent-pending methyl-DNA biomarkers for colorectal neoplasia to develop a sensitive and specific blood test for the earliest stages of colorectal cancer and pre-invasive neoplasia. Initial clinical trial results for our test are reported here.
To support our biomarker product development, we have also invented improved methods to purify rare circulating molecules and cells from clinical specimens.
Clinical Genomics includes experts in the science and business of molecular diagnostics as well as institutional, commercial and clinical collaborative partners that understand this market.